Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
MetaVia Inc. is a biotechnology company focused on developing pharmaceuticals for cardiometabolic diseases, including treatments for MASH and obesity. Its core programs include DA-1241, a GPR119 agonist for liver and diabetes, and DA-1726, a dual GLP-1 and glucagon receptor agonist for weight loss. The company advances its products through clinical trials, leveraging proprietary compounds, licensing agreements, and strategic collaborations in the biotech and pharmaceutical markets.
This description was generated via AI from an annual report. Updated about 1 year ago.